GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.
The user is considering making a homemade topical finasteride solution using an ethanol-based carrier. They are inquiring if a solution containing partially denatured ethyl alcohol and benzalkonium chloride is suitable.
The user is concerned about low DHT levels due to using saw palmetto in Foligain supplements and is considering trying finasteride. They seek advice on whether finasteride will also lower DHT and how to manage DHT levels.
The user is considering combining finasteride and minoxidil tablets into a topical solution that already includes Garnier Fructis stemoxydine and CB0103. They are seeking advice on whether this combination is effective and safe.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
The conversation discusses using retinol to enhance minoxidil's effectiveness for hair loss, with a user considering The Ordinary's 0.5% retinol and seeking advice on azelaic acid concentration. Other users suggest using tretinoin instead and consider pre-formulated products combining minoxidil, tretinoin, and azelaic acid, but the original poster has not seen improvement from dermarolling.
The conversation discusses using topical finasteride with propylene glycol, which causes scalp dryness or dandruff. The user also uses Nizoral, Nioxin, and DHT oil, and considers using a scalp conditioner to alleviate dryness.
The conversation discusses using oral castor oil as a hair growth stimulant for beard and scalp hair. One user questions its use, noting castor oil is typically a laxative in the Philippines.
Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.
Finasteride may cause elevated liver enzymes, potentially leading to liver issues, though this is rare. Users should monitor liver function and consider topical alternatives if liver sensitivity occurs.
Tretinoin can make minoxidil more effective for hair loss treatment, but some users did not see improved hair density with this combination and had better results with dutasteride.
FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.
Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.
Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.
The user is considering mixing 15mg of dutasteride with 60ml of castor oil for mesotherapy (micro-needling) to treat hair loss. They are asking if this method is viable.
The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.
User experienced high E2 levels after taking finasteride and sought advice on lowering E2 with supplements like Tonkat ali, Fadogia, and Boron. They also used DIM, zinc, and magnesium but avoided using an AI.
A 22-year-old is experiencing hair loss after transitioning from fem HRT to DIY testosterone therapy and is considering using Dutasteride while also taking Saw Palmetto. They are concerned about the impact on virilization and proper development.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
Topical androgen receptor antagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.
Retinol or tretinoin may improve minoxidil absorption and effectiveness. The user is considering using The Ordinary's 1% retinol as tretinoin is hard to get in their country.
Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.
NAD⁺ precursors and EGCG may increase hair density, but users report mixed results with no significant hair gains. Some users suggest combining these with finasteride or dutasteride for better results.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.